These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11426017)

  • 41. Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.
    Park JS; Park MC; Song JJ; Park YB; Lee SK; Lee SW
    Arthritis Res Ther; 2015 Mar; 17(1):77. PubMed ID: 25889905
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
    Khanna D; Furst DE; Hays RD; Park GS; Wong WK; Seibold JR; Mayes MD; White B; Wigley FF; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally EV; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice.
    Jordan S; Maurer B; Toniolo M; Michel B; Distler O
    Rheumatology (Oxford); 2015 Aug; 54(8):1454-8. PubMed ID: 25762528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oesophageal manometry in early and definite systemic sclerosis.
    Airò P; Della Casa D; Danieli E; Missale G; Cattaneo R; Cestari R
    Clin Rheumatol; 2005 Aug; 24(4):370-6. PubMed ID: 15592901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset.
    Derk CT; Huaman G; Jimenez SA
    Br J Dermatol; 2008 May; 158(5):1063-8. PubMed ID: 18284395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis.
    D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M
    Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic sclerosis and malignancy.
    Sargin G; Senturk T; Cildag S
    Int J Rheum Dis; 2018 May; 21(5):1093-1097. PubMed ID: 29673080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis.
    Hudson M; Taillefer S; Steele R; Dunne J; Johnson SR; Jones N; Mathieu JP; Baron M
    Clin Exp Rheumatol; 2007; 25(5):754-7. PubMed ID: 18078627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis.
    Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Allanore Y; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):114-121. PubMed ID: 28664832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serological and clinical profile of systemic sclerosis: analysis in a cohort of patients from a single center in Northern Italy.
    Priora M; Manetta T; Scarati M; Parisi S; Laganà A; Peroni CL; Bruzzone M; Borrelli R; Rende M; Mengozzi G; Fusaro E
    G Ital Dermatol Venereol; 2018 Feb; 153(1):33-38. PubMed ID: 27055150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry.
    Tolosa-Vilella C; Morera-Morales ML; Simeón-Aznar CP; Marí-Alfonso B; Colunga-Arguelles D; Callejas Rubio JL; Rubio-Rivas M; Freire-Dapena M; Guillén-Del Castillo A; Iniesta-Arandia N; Castillo-Palma MJ; Egurbide-Arberas M; Trapiellla-Martínez L; Vargas-Hitos JA; Todolí-Parra JA; Rodriguez-Carballeira M; Marin-Ballvé A; Pla-Salas X; Rios-Blanco JJ; Fonollosa-Pla V;
    Semin Arthritis Rheum; 2016 Oct; 46(2):200-208. PubMed ID: 27312381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of the Health Assessment Questionnaire for Japanese patients with systemic sclerosis--measuring functional impairment in systemic sclerosis versus other connective tissue diseases.
    Morita Y; Muro Y; Sugiura K; Tomita Y; Tamakoshi K
    Clin Exp Rheumatol; 2007; 25(3):367-72. PubMed ID: 17631731
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systemic sclerosis-rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity.
    Szücs G; Szekanecz Z; Zilahi E; Kapitány A; Baráth S; Szamosi S; Végvári A; Szabó Z; Szántó S; Czirják L; György Kiss C
    Rheumatology (Oxford); 2007 Jun; 46(6):989-93. PubMed ID: 17384178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG).
    Harding S; Khimdas S; Bonner A; Baron M; Pope J;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S38-43. PubMed ID: 22691207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
    Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.
    van den Hombergh WMT; Kersten BE; Knaapen-Hans HKA; Thurlings RM; van der Kraan PM; van den Hoogen FHJ; Fransen J; Vonk MC
    Trials; 2018 Aug; 19(1):449. PubMed ID: 30134971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucocorticoid effects on myocardial performance in patients with systemic sclerosis.
    Antoniades L; Sfikakis PP; Mavrikakis M
    Clin Exp Rheumatol; 2001; 19(4):431-7. PubMed ID: 11491499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.